AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Results of Operations and Financial ConditionItem 2.02 of the Original Filing, the reference to "March 16, 2017" should have been to "March 16, 2018," as corrected in this amendment.
AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Results of Operations and Financial Condition
| Item 2.02 |
Results of Operations and Financial Condition. |
On March 16, 2018, Avadel Pharmaceuticals plc (the "Company") filed its Form 10-K for the year ended December 31, 2017. During the Company's finalization of its Form 10-K, Avadel made certain adjustments that resulted in its previously reported earnings per share results for the full year 2017 to increase by $0.02. GAAP earnings for the full year 2017 increased to $68.271 millionfrom the $67.254 millionamount previously stated in Avadel's press release dated March 8, 2018; and GAAP earnings per share for the full year 2017 increased to $1.63 from the $1.61 amount previously stated in the press release. To review the Company's full financial statements for the full year 2017, please see the Company's Form 10-K filed March 16, 2018.
The information responsive to this Item 2.02 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.
